Protalix BioTherapeutics (PLX) Misses Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts PLX Hot Sheet
Price: $2.32 --0%
EPS Growth %: +400.0%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: +400.0%
Financial Fact:
RESEARCH AND DEVELOPMENT EXPENSES: -6.35M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Protalix BioTherapeutics (NYSE: PLX) reported Q2 EPS of ($0.11), $0.06 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $8.75 million versus the consensus estimate of $15.1 million.
Cash, cash equivalents and short-term bank deposits were approximately $28.6 million at June 30, 2022.
For earnings history and earnings-related data on Protalix BioTherapeutics (PLX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Solstice acquiring Element Solutions in $14.5B cash and stock deal
- Deutsche sees attractive entry point in Consumer Staples, Real Estate
- Solstice to acquire Element Solutions in $14.5B deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
